Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | $541.74M |
| Gross Profit (TTM) | $394.97M |
| EBITDA | $104.21M |
| Operating Margin | 16.30% |
| Return on Equity | 6.93% |
| Return on Assets | 3.76% |
| Revenue/Share (TTM) | $6.86 |
| Book Value | $16.50 |
| Price-to-Book | 3.39 |
| Price-to-Sales (TTM) | 8.27 |
| EV/Revenue | 7.67 |
| EV/EBITDA | 37.03 |
| Quarterly Earnings Growth (YoY) | 288.90% |
| Quarterly Revenue Growth (YoY) | 21.50% |
| Shares Outstanding | $79.79M |
| Float | $79.28M |
| % Insiders | 0.54% |
| % Institutions | 112.66% |
Volatility is currently expanding
Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a debt-free balance sheet.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemo.
Veracyte is evolving into a multi-cancer clinical decision-making platform, leveraging evidence, payer coverage, and workflow integration for durable growth. Q1 2026 results showed 21% revenue growth, expanding gross margins (up to 76% non-GAAP), and strong operating leverage, with raised 2026 guidance and robust cash generation. Medicare coverage for TrueMRD in muscle-invasive bladder cancer and the upcoming Prosigna LDT launch in breast cancer expand VCYT's addressable market and reinforce its evidence-driven moat.
VCYT gains from strong Afirma and Decipher test growth, but macro pressures and competition pose risks. See what may shape its next move.
VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and no debt.
